← Edgewise Therapeutics, Inc. (EWTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Edgewise Therapeutics, Inc. (EWTX)
Pharmaceutical Preparations · market cap $4.4B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
4
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Edgewise Therapeutics (EWTX) is a clinical-stage biotech with a ~$4.9B market cap focused on muscle-directed therapies. Its pipeline spans three Phase 2 assets: EDG-7500 in hypertrophic cardiomyopathy (HCM) and sevasemten in both Becker and Duchenne muscular dystrophies. A Phase 2 readout flagged positive in June 2026 anchors near-term sentiment, but with only ~$33M cash and an estimated 2.3-month runway, imminent financing is a near-certainty.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-01-15 (est.)Phase 2 · Sevasemten Dose 1imp 7/10
- 2027-03-15 (est.)Phase 2 · Sevasemten Dose 2imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EDG-7500 | Phase 2 | Hypertrophic Cardiomyopathy |
| Sevasemten 10 mg | Phase 2 | Becker Muscular Dystrophy |
| Sevasemten Dose 1 | Phase 2 | Duchenne Muscular Dystrophy |
| Sevasemten Dose 2 | Phase 2 | Duchenne Muscular Dystrophy |
Price & technical context
3-month
+2.3%
6-month
+22.1%
12-month
+149.6%
52-wk range
$14.70–$48.35
vs 50-day MA
-5.5%
vs 200-day MA
+16.6%
Realized vol
72.4%
Max drawdown
-68.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EWTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.